We identified new cell cycle regulating miRNAs, miR-107 and miR-185, localized in frequently altered chromosomal regions in human lung cancers

Low expression of miR-107 was significantly associated with tumor progression and decreased survival in patients with non-small cell lung cancer

Suggest that miR-107 plays a key role in cisplatin resistance by targeting the CDK8 protein in non small cell lung cancer cells.

H19 can promote cell cycle progression of non-small cell lung cancer cells by down-regulating miR-107.

Findings show that miR-107 expression is downregulated in non-small cell lung cancer (NSCLC) and inversely correlate with BDNF. Also, they provide evidence that miR-107 could suppress NSCLC metastasis by targeting BDNF and indirectly regulating PI3K/AKT signaling pathway.

Results show that H19 regulates NF1 expression through competitive binding to microRNA-107, thereafter participating in non-small cell lung cancer (NSCLC) cells development.

Study provides evidence that miR-107 acts as a tumor suppressive RNA and regulates the proliferation of non-small cell lung cancer. Also, miR-107 targets IKBKG, a critical regulator of NF-kB activation.

expression level of FOXC2-AS1 in lung cancer (LCa) specimens was considerably higher than in normal tissues and correlated with higher incidence of distant metastasis and lower overall survival rate. miR-107 expression was found significantly reduced in LCa cell lines and tissues and showed a negative correlation with FOXC2-AS1. Luciferase reporter gene assay verified direct binding of FOXC2-AS1 to downstream miRNA-107.

Downregulation of oncogenic gene TGFbetaR2 by miRNA-107 suppresses non-small cell lung cancer.

circHIPK3 Acts as Competing Endogenous RNA and Promotes Non-Small-Cell lung cancer Progression through the miR-107/BDNF Signaling pathway.